Cytoablative treatments lead to severe damages on thymic epithelial cells (TECs), which result in delayed de novo thymopoïesis and a prolonged period […]

The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates […]

New anti-atherogenic strategies based on B cell modulation, and suggest that patients currently treated with CD20 antibodies for other immune-mediated […]

Inflammation is a prominent feature of ischemia-reperfusion injury (IRI) characterized by leukocyte infiltration and renal tubular injury. However, […]

The present invention relates to methods and pharmaceutical compositions for the treatment of Erythropoietic Protoporphyria. In particular, the […]

The invention relates to peptides derived from the MELOE antigen for therapeutic vaccination against cancer. A phase I clinical trial for ex-vivo […]

The severity of renal lesions after nephron reduction varied substantially among mouse strains and required activation of EGFR. Lipocalin 2 (Lcn2, […]

The present invention relates to a method for treating a subject suffering from a liver disease comprising a step of administering said subject with a […]

The present invention concerns an oligonucleotide modified by substitution at the 3’ or the 5’ end by at least triple alkyl chain or at least one […]

The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) […]